JACOBS LEVY EQUITY MANAGEMENT, INC - ARBUTUS BIOPHARMA CORP ownership

ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 110 filers reported holding ARBUTUS BIOPHARMA CORP in Q2 2022. The put-call ratio across all filers is 0.82 and the average weighting 0.2%.

Quarter-by-quarter ownership
JACOBS LEVY EQUITY MANAGEMENT, INC ownership history of ARBUTUS BIOPHARMA CORP
ValueSharesWeighting
Q3 2022$351,000
+111.4%
183,867
+230.0%
0.00%
+200.0%
Q1 2022$166,000
-23.5%
55,7130.0%0.00%0.0%
Q4 2021$217,000
+239.1%
55,713
+82.1%
0.00%0.0%
Q2 2019$64,000
-17.9%
30,593
+40.4%
0.00%0.0%
Q1 2019$78,00021,7960.00%
Other shareholders
ARBUTUS BIOPHARMA CORP shareholders Q2 2022
NameSharesValueWeighting ↓
JACOB ASSET MANAGEMENT OF NEW YORK LLC 340,000$1,459,0000.53%
RTW INVESTMENTS, LP 4,733,323$20,306,0000.31%
APIS CAPITAL ADVISORS, LLC 70,000$300,0000.29%
Hudson Bay Capital Management LP 1,800,000$7,722,0000.10%
COWEN AND COMPANY, LLC 249,215$1,069,0000.05%
Kerrisdale Advisers, LLC 100,000$429,0000.05%
Woodline Partners LP 496,172$2,129,0000.04%
Shay Capital LLC 60,000$257,0000.03%
Walleye Capital LLC 231,037$991,0000.03%
BOOTHBAY FUND MANAGEMENT, LLC 212,700$912,0000.02%
View complete list of ARBUTUS BIOPHARMA CORP shareholders